Navigation Links
Repligen Announces Completion of Patient Enrollment in Phase 2b Clinical Trial of RG2417 for Bipolar Depression
Date:9/30/2010

rapies are approved for the treatment of bipolar disorder, many individuals are unable to tolerate the treatment-related side effects, and incomplete clinical response, relapse and recurrence remain common clinical problems.  There are more than five million adults worldwide with bipolar disorder, an area of high unmet medical need due to the ineffectiveness and significant side effects of current therapies.

About Repligen Corporation

Repligen Corporation is a biopharmaceutical company focused on building an integrated company by developing and marketing innovative drugs that deliver the benefits of protein therapies in the fields of neurology and gastroenterology.  We have a core competency in large-scale protein manufacturing and have out-licensed certain biologics intellectual property, which provide ongoing sources of revenue.  Repligen's corporate headquarters are located at 41 Seyon Street, Building #1, Suite 100, Waltham, MA 02453.  Additional information may be requested at www.repligen.com.

This press release contains forward-looking statements which are made pursuant to the safe harbor provisions of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. The forward-looking statements in this release do not constitute guarantees of future performance. Investors are cautioned that statements in this press release which are not strictly historical statements, including, without limitation, statements regarding future financial performance and position, management's strategy, plans and objectives for future operations, plans and objectives for product development, plans and objectives for present and future clinical trials and results of such trials, plans and objectives for regulatory approval, litigation, intellectual property protection, product development, manufacturing plans and performance, project
'/>"/>

SOURCE Repligen Corporation
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related medicine technology :

1. Repligen to Present at the Rodman & Renshaw Annual Global Investment Conference
2. Repligen Announces Conference Call of First Quarter Fiscal Year 2011 Results
3. Repligen Reports Notice of Allowance of a United States Patent Covering the Use of Uridine to Treat the Symptoms of Bipolar Disorder
4. Repligen Receives Notice of Allowance for Recombinant Protein A Patent
5. Repligen Announces Long Term Supply Agreement with GE Healthcare for Recombinant Protein A
6. Repligen Reports Phase 3 Clinical Trial Results of RG1068 in Pancreatic Imaging
7. Repligen Announces Plans to Initiate a Phase 2b Trial for RG2417 in Bipolar Disorder
8. Repligen Receives FDA Fast Track Designation for RG1068 for Pancreatic Imaging
9. Repligen Initiates Phase 3 Clinical Trial of RG1068 for Pancreatic MRI Imaging
10. Repligen Reports Positive Phase 2a Clinical Trial Results of RG2417 for Symptoms of Bipolar Disorder
11. Warner Chilcott Announces the Closing of its $500 Million Senior Notes Offering
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/1/2014)...   Royal Philips (NYSE: ... and eCareCompanion telehealth applications have received 510(k) clearance ... A part of Philips Hospital to Home,s ... are focused on patient care within the home ... available through the cloud-based digital health platform, which ...
(Date:10/1/2014)... LAUSANNE , Suisse, October 1, 2014 /PRNewswire/ ... génomique clinique et dans le domaine de l,analyse ... a lancé aujourd,hui une solution de diagnostic in ... d,exécuter une analyse complète de la mucoviscidose dans ... d,identifier et de caractériser tous les types de ...
(Date:9/30/2014)... 30, 2014  Wrightington, Wigan ... MDRX ) are delighted to announce WWL,s ... new health information system. The system will be implemented ... the way WWL delivers healthcare in the future. ... record of on-time and on-budget system implementations as well ...
Breaking Medicine Technology:Philips Secures 510(k) Clearance to Market the First Clinical Applications for its new Digital Health Platform 2Philips Secures 510(k) Clearance to Market the First Clinical Applications for its new Digital Health Platform 3Philips Secures 510(k) Clearance to Market the First Clinical Applications for its new Digital Health Platform 4Sophia Genetics lance une analyse complète du gène CFTR dans un essai clinique SGN 2Sophia Genetics lance une analyse complète du gène CFTR dans un essai clinique SGN 3Wrightington, Wigan and Leigh NHS Foundation Trust selects Allscripts Sunrise 2Wrightington, Wigan and Leigh NHS Foundation Trust selects Allscripts Sunrise 3Wrightington, Wigan and Leigh NHS Foundation Trust selects Allscripts Sunrise 4
... , July 28 HemaQuest Pharmaceuticals, a ... sickle cell disease, beta thalassemia and EBV-related cancers, announced ... to its Series B financing by new investor, Latterell ... financing to $16M . The financing is intended ...
... July 27 /PRNewswire-Asia/ -- WuXi PharmaTech (Cayman) Inc. ... Proxy Advisory Services,("ISS"), a leading independent proxy voting and corporate ... River,s proposed,acquisition of WuXi. Two other proxy advisory services, Glass ... the,transaction. , , ...
Cached Medicine Technology:HemaQuest Pharmaceuticals Raises Additional $4M to Bring Total to $16M in Series B Financing 2ISS Recommends That WuXi Shareholders Vote for Proposed Combination With Charles River 2ISS Recommends That WuXi Shareholders Vote for Proposed Combination With Charles River 3ISS Recommends That WuXi Shareholders Vote for Proposed Combination With Charles River 4ISS Recommends That WuXi Shareholders Vote for Proposed Combination With Charles River 5
(Date:10/1/2014)... October 01, 2014 Lifeinsurance-policy.com has ... the best life insurance prices for smokers. , Smoking ... insurance premiums. Comparing quotes is the best method to ... quotes for customers who need coverage. , Whole ... duration of the policy. Since the coverage is permanent, ...
(Date:10/1/2014)... 2014 Phoseon Technology, the pioneer in ... expand the business worldwide. This rapid growth includes increased ... for manufacturing efforts. The company has experienced average annual ... and expects this growth to continue in the future ... worldwide adoption. , “We are very pleased that ...
(Date:10/1/2014)... Farmington Company today announced it ... and visual identity helping brokers, consultants and companies ... to create greater benefit communication synergies. They unveiled ... empowering customers to better leverage Farmington Company’s industry-tested ... of the rebrand is the refreshed tagline: For ...
(Date:10/1/2014)... A new genetic finding from Duke Medicine suggests that ... depression might also be hard-wired to gain weight when ... disease. , An estimated 13 percent of people, all ... and knowing this could help them reduce heart disease ... and stress management. , "Genetic susceptibility, psychosocial stress and ...
(Date:10/1/2014)... 2014 Between 23 million and 50 ... according to figures from the National Institutes of Health ... and many of them have something else in common: ... celiac disease. Gluten Free Therapeutics, makers of CeliVites ... celiac disease by publishing a series of blog posts ...
Breaking Medicine News(10 mins):Health News:Affordable Whole Life Insurance Premiums for Smokers! 2Health News:Phoseon Technology Continues to Drive Growth Worldwide 2Health News:Farmington Company Launches Rebrand and New Positioning 2Health News:Gene interacts with stress and leads to heart disease in some people 2Health News:Informative New Blog Series Underscores Link Between Celiac Disease and Other Autoimmune Disorders 2Health News:Informative New Blog Series Underscores Link Between Celiac Disease and Other Autoimmune Disorders 3
... COVER: "Splitsville" (p. 46). Senior Editor David J. Jefferson ... classmates from Ulysses S.,Grant High School, class of ,82 ... interviews with former classmates, Jefferson tells the,stories of those ... the nuclear,family, the first for which divorce was just ...
... The Barbara Ann Karmanos,Cancer Institute researchers today presented, ... in San Diego, CA, the potential benefits,of Thymoquinone ... black seeds (Nigella,sativa), in treating pancreatic cancer., ... black seeds have been consumed in Asia, Africa ...
... April 12 Hundreds of,Service Employees International Union ... tonight, renouncing recent actions by the,California Nurses Association ... members made their voices heard during the Labor,Notes ... Rose,Ann DeMoro was scheduled to speak but cancelled ...
... condoms, vasectomy , , SATURDAY, April 12 (HealthDay News) -- For now, ... meager choices: A vasectomy -- meant to be permanent -- and ... is under development and that more choices will be here soon. ... off, but it,s getting closer. , "It has been ...
... with older, poorer, less educated populations likely due to ... , ANN ARBOR, Mich. More than a third of ... a huge increase from just a decade ago and a ... of Michigan study reveals major gaps in the availability of ...
... Home Operator Continuing to Jeopardize Residents, Care, ... Millbrae Convalescent Hospital will launch their second strike ... management,s unwillingness to,bargain fairly over the workers, proposals ... set to begin at 6 a.m. on Tuesday, ...
Cached Medicine News:Health News:NEWSWEEK: Media Lead Sheet/April 21, 2008 Issue (on newsstands Monday, April 14). 2Health News:NEWSWEEK: Media Lead Sheet/April 21, 2008 Issue (on newsstands Monday, April 14). 3Health News:NEWSWEEK: Media Lead Sheet/April 21, 2008 Issue (on newsstands Monday, April 14). 4Health News:NEWSWEEK: Media Lead Sheet/April 21, 2008 Issue (on newsstands Monday, April 14). 5Health News:Karmanos Researchers Report Enhanced Chemosensitivity of Pancreatic Cancer Cells by Black Seed Component 2Health News:Karmanos Researchers Report Enhanced Chemosensitivity of Pancreatic Cancer Cells by Black Seed Component 3Health News:SEIU Members Stand Up for the Future of the Labor Movement and the Interests of All Workers 2Health News:Male Contraception: Progress Slow but Steady 2Health News:Male Contraception: Progress Slow but Steady 3Health News:National hospice study reveals gaps in service 2Health News:National hospice study reveals gaps in service 3Health News:National hospice study reveals gaps in service 4
Batch Detection of Soluble Fibrin Monomer Complexes by the Hemagglutination Technique, 40 tests....
For use with catalog #0540....
Enzyme Immunoassay of D-Dimer by ELISA Method, 96 tests....
Lupus Anticoagulant-Sensitive APTT Reagent.Cephalin with particulate activator (silica), freeze-dried....
Medicine Products: